medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2015, Número 4

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (4)


Manifestaciones hematológicas, etiopatogenia y exámenes de laboratorio en la enfermedad por virus Ébola

Jaime FJC, Céspedes RLE, Roque GW, Leiva PY

Idioma: Español
Referencias bibliográficas: 35
Paginas: 385-392
Archivo PDF: 59.82 Kb.


RESUMEN

La enfermedad por el virus del Ébola es una dolencia con frecuencia fatal, causada por una de las cinco cepas altamente contagiosas de este virus que afecta, tanto a animales como a seres humanos, cuya tasa de letalidad puede llegar al 90 %. Desde su detección se han producido varios brotes, incluido el último en abril de 2014. Una de las manifestaciones más importantes es el síndrome hemorrágico que suele darse en las últimas etapas de la enfermedad, cuadro que no ocurre en todos los pacientes afectados. Se describen las principales manifestaciones hematológicas presentes en esta entidad, así como algunos aspectos de su etiopatogenia y exámenes de laboratorio útiles en el manejo de estos pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Centers for Disease Control and Prevention. 2014 Ebola Outbreak in West Africa. [ sitio en Internet] [citado 2015 may 15]. Disponible en: (http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html.)

  2. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011 Mar 5;377(9768):849-62.

  3. Hartman AL, Towner JS, Nichol ST. Ebola and Marburg hemorrhagic fever. Clin Lab Med. 2011 Mar;30(1):161-77.

  4. World Health Organization. Ebola vi-rus disease in Guinea. [sitio en Internet] [citado 2015 feb 4]. Disponible en: http://www.afro.who.int/en/clusters-aprogrammes/ dpc/epidemic-a-pandemic-alert-and-response/outbreak-news/4063- ebola-hemorrhagic-fever-in-guinea.html

  5. World Health Organization. Ebola virus disease fact sheet. [sitio en Internet] [citado 2015 feb 4]. Disponible en: http://www.who.int/mediacentre/factsheets/fs103/en.

  6. Beeching NJ, Fletcher TE, Hill DR, Thomson GL. Travellers and viral haemorrhagic fevers: what are the risks? Int J Antimicrob Agents. 2010 Nov;36 (Suppl 1):S26-35

  7. Centers for Diseases Control and Prevention. Outbreaks chronology: Ebola virus disease [sitio en Internet] [citado 2015 feb 4]. Disponible en: http://www.cdc.gov/vhf/ebola/index.html

  8. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014 Oct 9;371(15):1418-25.

  9. McElroy A. Understanding bleeding in ebola virus disease. Clin Adv Hematol Oncol. 2015 Jan;13(1):29-31.

  10. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015 Jan 1;372(1):40-7.

  11. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999 Feb;179 (Suppl 1):S1-7.

  12. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003 Dec 1;188(11):1618-29.

  13. Hensley LE, Geisbert TW.The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost. 2005 Aug;94(2):254-61.

  14. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner J. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014 Aug 15;210(4):558-66.

  15. Bray M. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol. 2013 Jan 24;8:411-40.

  16. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204 (Suppl 3):S810-6.

  17. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4719-24.

  18. Fabozzi G, Nabel CS, Dolan MA, Sullivan NJ. Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J. Virol.2011;85: 2512–23.

  19. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014;14,36-49.

  20. Levi M, Toh CH, Thachil J, Watson HG. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2010 Apr;145(1):24-33.

  21. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis. 2004 Aug;4(8):487-98.

  22. García-Dorival I, Wu W, Dowall S, Armstrong S, Touzelet O, Wastling J, Barr JN. Elucidation of the Ebola virus VP24 cellular interactome and disruption of virus biology through targeted inhibition of host-cell protein function. J Proteome Res. 2014 Nov 7;13(11):5120-35.

  23. Misasi J, Sullivan NJ.Camouflage and misdirection: the full-on assault of ebola virus disease.Cell. 2014 Oct 23;159(3):477-86.

  24. Mateo M, Reid SP, Leung LW, Basler CF, Volchkov VE. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J. Virol. 2011;84: 1169-75.

  25. Bradfute SB, Braun DR, Shamblin JD, Geisbert JB, Paragas J, Garrison A, et al. Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis. 2007;196 (Suppl 2):S296.

  26. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204(Suppl 3):S810-S6.

  27. Basler CF. Interferon antagonists encoded by emerging RNA viruses. In: Modulation of Host Gene Expression and Innate Immunity by Viruses, Palese P (Ed), Springer, Dordrecht, the Netherlands. 2005. p.197.

  28. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014; 371:2394.

  29. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa--clinical manifestations and management. N Engl J Med. 2014;371:2054.

  30. Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, Nabel GJ. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science. 1998 Feb 13;279(5353):1034-7.

  31. Yang Z, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ: Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000 Aug;6(8):886-9.

  32. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003 Dec;163(6):2371-82.

  33. Moncada S, Palmer RMJ, Higgs EA: Relationship between prostacyclin and nitric oxide in the thrombotic process. Thromb Res Suppl. 1990; XI:3-13

  34. Mantovani A, Bussolino F, Dejana E: Cytokine regulation of endothelial cell function. EMBO J. 1992; 6:2591-99

  35. Streinu-Cercel A.Ebola virus disease - a global threat. Germs. 2014 Sep 1;4(3):58.




2020     |     www.medigraphic.com